Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

t2 biosystems - TTOO

TTOO

Close Chg Chg %
0.55 -0.02 -3.28%

Open Market

0.53

-0.02 (3.28%)

Volume: 278.34K

Last Updated:

Nov 14, 2024, 10:08 AM EDT

Trade Now

Company Overview: t2 biosystems - TTOO

TTOO Key Data

Open

$0.59

 Day Range

0.52 - 0.59

52 Week Range

0.51 - 8.38

 Market Cap

$9.09M

Shares Outstanding

17.48M

 Public Float

5.78M

Beta

0.38

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$9.29

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

862.63K

  

TTOO Performance

1 Week
 
 -5.50%
 
1 Month
 
 -60.86%
 
3 Months
 
 -85.35%
 
1 Year
 
 -85.95%
 
5 Years
 
 -99.99%
 

TTOO Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 1
Full Ratings ➔

About t2 biosystems - TTOO

T2 Biosystems, Inc. is a vitro diagnostics company, which engages in the development of detection of sepsis-causing pathogens. It offers T2Dx instrument, T2Bacteria, T2Candida, T2Biothreat panels, and T2MR technology. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.

TTOO At a Glance

T2 Biosystems, Inc.
101 Hartwell Avenue
Lexington, Massachusetts 02421
Phone 1-781-761-4646 Revenue 7.19M
Industry Medical Specialties Net Income -50,077,000.00
Sector Health Technology Employees 113
Fiscal Year-end 12 / 2024
View SEC Filings

TTOO Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 2.277
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -1.084
Enterprise Value to Sales 6.977
Total Debt to Enterprise Value 0.986

TTOO Efficiency

Revenue/Employee 63,654.867
Income Per Employee -443,159.292
Receivables Turnover 5.065
Total Asset Turnover 0.208

TTOO Liquidity

Current Ratio 0.447
Quick Ratio 0.361
Cash Ratio 0.279

TTOO Profitability

Gross Margin -122.744
Operating Margin -655.54
Pretax Margin -696.191
Net Margin -696.191
Return on Assets -144.89
Return on Equity N/A
Return on Total Capital -233.329
Return on Invested Capital N/A

TTOO Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital 230.631
Total Debt to Total Assets 142.248
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital 30.743
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for T2 Biosystems - TTOO

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
18.13M 28.06M 22.30M 7.19M
Sales Growth
+117.52% +54.76% -20.50% -67.75%
Cost of Goods Sold (COGS) incl D&A
20.64M 20.70M 20.95M 16.02M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
3.16M 2.54M 2.27M 859.00K
Depreciation
3.16M 2.54M 2.27M 859.00K
Amortization of Intangibles
- - - -
-
COGS Growth
+23.15% +0.29% +1.19% -23.52%
Gross Income
(2.51M) 7.36M 1.35M (8.83M)
Gross Income Growth
+70.17% +392.56% -81.58% -751.59%
Gross Profit Margin
-13.87% +26.21% +6.07% -122.74%
2020 2021 2022 2023 5-year trend
SG&A Expense
37.68M 50.33M 55.40M 38.32M
Research & Development
16.92M 21.80M 25.77M 13.49M
Other SG&A
20.76M 28.53M 29.63M 24.83M
SGA Growth
-13.63% +33.56% +10.08% -30.82%
Other Operating Expense
- - - -
-
Unusual Expense
(256.00K) 1.01M 1.91M (2.91M)
EBIT after Unusual Expense
(39.94M) (43.98M) (55.96M) (44.24M)
Non Operating Income/Expense
76.00K 318.00K 39.00K (495.00K)
Non-Operating Interest Income
- 14.00K 112.00K 8.00K
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
6.93M 5.58M 6.08M 5.34M
Interest Expense Growth
-1.87% -19.57% +9.11% -12.18%
Gross Interest Expense
6.93M 5.58M 6.08M 5.34M
Interest Capitalized
- - - -
-
Pretax Income
(46.80M) (49.24M) (62.00M) (50.08M)
Pretax Income Growth
+20.69% -5.22% -25.92% +19.23%
Pretax Margin
-258.12% -175.50% -277.98% -696.19%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(46.80M) (49.24M) (62.00M) (50.08M)
Minority Interest Expense
- - - -
-
Net Income
(46.80M) (49.24M) (62.00M) (50.08M)
Net Income Growth
+20.69% -5.22% -25.92% +19.23%
Net Margin Growth
-258.12% -175.50% -277.98% -696.19%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(46.80M) (49.24M) (62.00M) (50.08M)
Preferred Dividends
- - - 330.00K
-
Net Income Available to Common
(46.80M) (49.24M) (62.33M) (50.08M)
EPS (Basic)
-1928.5 -1549.8 -1222.121 -19.1867
EPS (Basic) Growth
+70.25% +19.64% +21.14% +98.43%
Basic Shares Outstanding
24.27K 31.77K 51.00K 2.61M
EPS (Diluted)
-1928.5 -1549.8 -1222.121 -19.1867
EPS (Diluted) Growth
+70.25% +19.64% +21.14% +98.43%
Diluted Shares Outstanding
24.27K 31.77K 51.00K 2.61M
EBITDA
(37.04M) (40.44M) (51.77M) (46.29M)
EBITDA Growth
+23.49% -9.16% -28.04% +10.58%
EBITDA Margin
-204.31% -144.11% -232.12% -643.60%

Snapshot

Average Recommendation HOLD Average Target Price 5.00
Number of Ratings 1 Current Quarters Estimate N/A
FY Report Date N/A Current Year's Estimate N/A
Last Quarter’s Earnings -0.66 Median PE on CY Estimate N/A
Year Ago Earnings -19.19 Next Fiscal Year Estimate N/A
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates N/A N/A N/A N/A
Mean Estimate N/A N/A N/A N/A
High Estimates N/A N/A N/A N/A
Low Estimate N/A N/A N/A N/A
Coefficient of Variance N/A N/A N/A N/A

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 0 0 0
OVERWEIGHT 0 0 0
HOLD 1 1 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Hold Hold Hold

Insider Actions for T2 Biosystems - TTOO

Date Name Shares Transaction Value
May 14, 2024 CR Group LP 4,595,977 Conversion of derivative security 0.00
May 14, 2024 CR Group LP 4,704,729 Conversion of derivative security 0.00
May 8, 2024 CR Group LP 266,038 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 8, 2024 CR Group LP 3,548,707 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 8, 2024 CR Group LP 2,879,929 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 28, 2024 John J. Sperzel See Remarks; Director 400 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 28, 2024 John J. Sperzel See Remarks; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 28, 2024 Michael Terrence Gibbs General Counsel 135 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 28, 2024 Michael Terrence Gibbs General Counsel N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 28, 2024 John M. Sprague Chief Financial Officer 141 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Feb 28, 2024 John M. Sprague Chief Financial Officer N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Nov 29, 2023 Brett Giffin Chief Commercial Officer 3,586 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Nov 29, 2023 Brett Giffin Chief Commercial Officer 3,049 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $0.65 per share 1,981.85
Nov 29, 2023 Brett Giffin Chief Commercial Officer 2,667 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

T2 Biosystems in the News